Furthermore, differences in uptake were found within the tumour itself, suggesting that [18F]PARP1‐inhibitor PET may be able to visualise differences in PARP1 expression within a tumour and between different metastases in the same patient. This evidence concerns the gene PARP1 and neoplasm.